Impact of age on adherence and efficacy of peanut oral‐immunotherapy using a standardized protocol

Abstract

Peanut oral immunotherapy (POIT) has been shown to be an effective therapy in peanut allergic children, as it improves food allergy‐related quality of life ^[1‐2]. Randomized controlled trials and observational, real world studies have shown that POIT may be effective and safe in children of all ages, although starting POIT at a younger age may be more efficacious and safer ^{[3,5, 8]}. Furthermore, initiation of POIT at a younger age may have higher rates of sustained unresponsiveness ^[3]. However, there has not been formal evaluation of this concept, using a standardized protocol ^[6]. The aim of our study was to examine associations between the age at initiation of POIT, and the safety of POIT, using a standardized protocol for all patients.